Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AT193 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AT193 | EXPERIMENTAL | Topical applied daily |
| Placebo | PLACEBO_COMPARATOR | Topical applied daily |
| Name | Type | Description |
|---|---|---|
| AT193 | DRUG | Topical |
Inclusion Criteria: * Diagnosis of HS or signs and symptoms consistent with HS for at least 3 months before screening in the judgment of the investigator. * Stable disease for at least 2 months before screening in the judgment of the investigator. * A woman of childbearing potential must use approp...
Top 15 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib, Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | povorcitinib, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Remibrutinib, Secukinumab |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE2 | Duvakitug, Brivekimig, SAR445399 |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY072 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Olatorepatide |
| Oruka Therapeutics, Inc. | ORKA | 1 | PHASE2 | ORKA-002 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE1 | SAR447971 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE1 | Soquelitinib |